← board
BFRIW
distress 6/10 · elevated risk$0.04-43%today-45% from 52w high
Revenue
$10M
Liquidity
$6M
Runway
0.7 yrs
Shares 1y
+20%
Price & events
-45.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-42.9%
1D
+22.4%
1W
-42.9%
1M
-42.9%
3M
—
6M
—
1Y
—
2Y
—
5Y
-45.5%
All
Overview
- Market Cap
- $460.92K
- Volume
- 1.11K
- 52 Week Range
- $0.03 – $0.07
- Total Shares
- 12.80M
- Float Shares
- 9.08M
- RVOL
- 24.18x
- Beta
- 0.82
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2026-02-23fda agreementPTAB final decision unpatentable Sun patent claimsSEC 8-K
- 2025-11-06partnershipXepi (ozenoxacin) · Asset purchase agreement to sell US license to Pelthos Therapeutics for up to $10M.SEC 8-K
- 2025-10-23partnershipAmeluz, RhodoLED · Closed restructuring and asset purchase agreement with Biofrontera AG, acquiring all US assets and rights, new earnout structure (12-15% of net sales), and $11M financing from existing investors.SEC 8-K
- 2025-06-30partnershipAmeluz · Signed agreement to acquire all US assets of Ameluz and RhodoLED from Biofrontera AGSEC 8-K
Approved drugs (2)
- AMELUZAMINOLEVULINIC ACID HYDROCHLORIDE2016 · Prescription
- AKTIPAKBENZOYL PEROXIDE2000 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-01Biofrontera Inc. Warrant 2021-27.10.26 on Biofrontera Financial Disclosures & SEC Filings - TradingView
- 2026-06-26Price to book forward of Biofrontera Inc. – NASDAQ:BFRIW - TradingView
- 2026-06-22Biofrontera Inc (BFRIW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
- 2026-06-17Biofrontera Inc (BFRIW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
- 2026-05-14Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update - GlobeNewswire
- 2026-03-19Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.